Eton Pharmaceuticals Gains FDA Fast Track for AMGLIDIA and Targets 2027 NDA with ASN-001 Acquisition

Eton Pharmaceuticals is compressing its rare disease regulatory calendar on multiple fronts simultaneously, a pipeline posture that carries distinct implications for QA and regulatory affairs teams managing parallel submission tracks. Q2 2026 product sales reached $37.6 million, a 99% year-over-year increase, with full-year revenue guidance revised upward to at least $145 million from a prior floor of $120 million.

The regulatory workload underpinning that growth is substantial. Eton submitted a Prior Approval Supplement (PAS) to the FDA to expand the indication for KHINDIVI, targeting a potential H1 2027 approval. Separately, AMGLIDIA received FDA Fast Track designation in endocrinology, accelerating the development timeline and increasing the frequency of FDA interactions that regulatory affairs leads will need to resource accordingly. Fast Track status also opens the door to rolling review, which shifts submission planning from a single-point event to an iterative documentation process.

The acquisition of late-stage candidate ASN-001 adds a third concurrent regulatory thread. Eton plans to initiate a bioavailability study and anticipates an NDA submission in H2 2027 upon study completion. The asset targets moderate infantile hemangiomas and is intended to complement the existing HEMANGEOL franchise, sharing commercial infrastructure. For operations teams, the bioavailability study design and data package will need to align with 21 CFR Part 211 manufacturing controls and ICH M9 biopharmaceutics classification expectations ahead of any NDA filing.

The HEMANGEOL relaunch, completed May 1, provides a near-term operational reference point. Approximately 95% of existing patients were transitioned to Eton's program by end of June, ahead of schedule, with a $0 copay patient support structure in place. That transition pace reflects the kind of supply continuity and serialization readiness that plant heads and distribution teams will recognize as a benchmark for rare disease product relaunches operating under constrained patient populations.

Eton also acquired U.S. commercialization rights to orphan drug IMPAVIDO, further extending a portfolio that now spans pediatric endocrinology, metabolic disease, and infantile hemangioma. Adjusted EBITDA guidance was raised to a margin of at least 35%, absorbing ASN-001 transaction and development costs.

The H2 2027 NDA target for ASN-001 sets a measurable checkpoint against which bioavailability study execution, CMC documentation, and regulatory submission readiness will all be assessed.

Source: Eton Pharmaceuticals via GlobeNewswire, August 13, 2026. Management conference call held same day at 4:30 PM ET.